Method for controlling charging of a power source of a hybrid vehicle
    2.
    发明授权
    Method for controlling charging of a power source of a hybrid vehicle 有权
    一种用于控制混合动力车辆的动力源的充电的方法

    公开(公告)号:US07605561B2

    公开(公告)日:2009-10-20

    申请号:US10711499

    申请日:2004-09-22

    IPC分类号: H02J7/14

    摘要: A method for controlling charging of a power source of a hybrid vehicle. The method includes determining a maximum output level of a primary power source, determining a state of charge of a secondary power source, determining a charge torque modifier value based on the maximum output torque level and the state of charge, determining a target torque level for an electrical machine based on the charge torque modifier value, and driving the electrical machine at the target torque level with the primary power source to charge the secondary power source.

    摘要翻译: 一种用于控制混合动力车辆的动力源的充电的方法。 该方法包括确定主电源的最大输出电平,确定次电源的充电状态,基于最大输出转矩电平和充电状态来确定电荷转矩修正值,确定目标转矩电平 基于电荷扭矩调节剂值的电机,并且利用主电源将电机驱动到目标转矩水平以对二次电源充电。

    Removal of selected factors from whole blood or its components
    8.
    发明授权
    Removal of selected factors from whole blood or its components 失效
    从全血或其组分中去除所选择的因子

    公开(公告)号:US5523096A

    公开(公告)日:1996-06-04

    申请号:US482315

    申请日:1995-06-06

    摘要: This invention provides a composition, device and method for the removal of selected factors, such as cytokines or pharmaceuticals, from a substance such as whole blood or plasma. Advantageously, the invention provides for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood. Pharmaceuticals can be removed from an individual's whole blood or plasma, such as for use in treating drug overdosage.

    摘要翻译: 本发明提供了用于从诸如全血或血浆的物质中除去选定因子如细胞因子或药物的组合物,装置和方法。 有利地,本发明提供了治疗或预防感染性休克综合征或其他由患者的细胞因子的存在所证实的条件,其通过使患者的全血与包含二氧化硅和表面处理材料(例如肝素,但优选人类)的组合物接触 血清白蛋白(HSA)。 治疗降低血液的细胞因子浓度。 药物可以从个体的全血或血浆中除去,例如用于治疗药物过量。